Rosen Law Firm Urges Zenas BioPharma Investors to Act Before June 16

NEW YORK, June 8, 2025 (GLOBE NEWSWIRE) – The Rosen Law Firm, a leading global law firm specializing in investor rights, has issued a call to action for investors of Zenas BioPharma, Inc. (NASDAQ: ZBIO) who have suffered losses exceeding $100,000. The firm reminds these investors of the critical June 16, 2025, deadline for participating as lead plaintiffs in a securities class action lawsuit initially filed by the firm. This legal action pertains to Zenas BioPharma's September 2024 initial public offering (IPO), during which the firm alleges that the registration statement contained materially false and misleading information regarding the company’s financial projections.

In a statement, Phillip Kim, Esq., a partner at Rosen Law Firm, highlighted the importance of this deadline, stating, "Investors who purchased Zenas BioPharma securities may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement. We encourage all affected investors to secure legal counsel promptly."

According to the details disclosed in the lawsuit, the registration statement issued by Zenas BioPharma overstated the company’s ability to sustain operations using existing cash and projected net proceeds from its IPO. Specifically, the firm asserts that the defendants made public statements that were materially inaccurate and negligently prepared, leading to significant financial harm once the true state of affairs was revealed to the market.

The Rosen Law Firm, recognized for its expertise in securities class actions, emphasizes selecting qualified legal representation. The firm has built a reputation for achieving high-profile settlements, including the largest securities class action settlement against a Chinese company at the time. Laurence Rosen, the firm’s founding partner, was acknowledged by Law360 as a Titan of the Plaintiffs’ Bar and has consistently been ranked among the top attorneys in the field.

Legal experts suggest that affected investors should act swiftly, as the process for becoming a lead plaintiff requires filing a motion with the court by the deadline. According to Dr. Sarah Johnson, Professor of Law at Yale University, “Participating as a lead plaintiff provides a unique opportunity for investors to influence the direction of the litigation and ensure their interests are adequately represented.”

The securities class action lawsuit remains open for participation, with the firm urging investors to join by visiting their website or calling for more information. Until a class is certified, those wishing to participate are advised to consult legal counsel of their choice. The firm underscores that an investor's ability to benefit from any potential recovery does not depend on being a lead plaintiff.

As this case unfolds, it not only reflects the ongoing challenges in the biotechnology sector but also highlights the importance of transparency in financial disclosures, particularly during IPOs. Investors are encouraged to remain vigilant and informed about the developments in this case, as its outcome could set significant precedents for future securities litigation in the healthcare industry.